Revenue: As of FY2026 Q2, the actual value is USD 49.19 M, beating the estimate of USD 45.45 M.

EPS: As of FY2026 Q2, the actual value is USD 0.1, missing the estimate of USD 0.1125.

EBIT: As of FY2026 Q2, the actual value is USD 19.08 M.

Second Quarter 2026 Financial Performance

Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, a substantial increase of 335% year-over-year. Net income margin was 22%, up 16 percentage points year-over-year. Adjusted EBITDA reached $20 million, growing by 32% year-over-year, and the Adjusted EBITDA margin was 41%, an increase of 6 percentage points year-over-year.

First Half 2026 Financial Performance

Net income attributable to SBC Medical Group Holdings Incorporated was $22 million, showing an 8% decrease year-over-year, with a net income margin of 24%, down 2 percentage points year-over-year. Adjusted EBITDA for the first half was $38 million, a 4% decrease year-over-year, and the Adjusted EBITDA margin was 42%, decreasing by 2 percentage points year-over-year. Annualized Return on Equity (ROE) was 17%, a decrease of 5 percentage points year-over-year.

Operational Metrics

As of the end of June 2026, the number of locations supported by SBC Medical Group Holdings Incorporated increased by 34 year-over-year to 287. The last-twelve-month number of patient visits reached 6.9 million, an increase of 10% year-over-year, with the average spend per visit at $287, up 9% year-over-year.

Cash Flow and Balance Sheet Highlights

Net cash provided by operating activities for the six months ended June 30, 2026, was $31,741,248, a significant improvement from - $6,411,168 for the same period in 2025. SBC Medical Group Holdings Incorporated held $184,311,213 in cash and cash equivalents as of June 30, 2026, an increase from $163,773,838 as of December 31, 2025.

Outlook and Guidance

SBC Medical Group Holdings Incorporated anticipates an annual increase of approximately $15 million in service fees from recent fee revisions. The company plans to deepen its multi-brand strategy in aesthetic dermatology, expand its non-aesthetic business, and accelerate global growth. With $184 million in cash, SBC Medical Group Holdings Incorporated intends to continue disciplined investment to drive sustained EPS growth and achieve fair equity valuation.